Chandigarh-based Ind-Swift Ltd has launched a new marketing division "Resurgence" to cater to critical care segments like anesthesiology, oncology and surgery. To begin with, Resurgence, the fifth marketing arm of the company, will start marketing anesthesiology drugs. Other segments would be added in a phased manner.

According to a company statement, Ind Swift is targeting a sales turnover of Rs 15 crores from Resurgence during the first year of its operation. The turnover is expected to grow to Rs 50 crores within three years. The Company has already inducted 50 new field staff and plans to add 100 more to take the total strength of its field staff to 900 in near future, the statement claimed.

The company release said that they have 10-12 oncology products in the pipeline.

According to Dr. G Munjal, chairman Indswift, the company is in the process of introducing globally acclaimed surgical products in Indian markets.

As per IMS/ORG, Anesthesiology is a rapidly growing segment having market of 40 crore with a growth trend of 19 per cent. The data does not truly reflect the market size of the Anesthesiology branch as institutions, hospitals, nursing homes are not covered by IMS. Oncology and Surgical drugs have market more than Rs 100 crore and 170 crore and growing at 11 per cent and 8.9 per cent respectively.

Ind Swift is also planning to launch new divisions focusing on Nephrology and Neuropsychiatry, medical devices, ortho and dental equipment. The company is aiming at having nine specially focused marketing divisions and hopes to achieve a sales target of Rs 325 crore with profitability of Rs 35 crore in next three years.